Pioneering CRISPR-powered medicine

By harnessing CRISPR-powered technology to target antibiotic-resistant bacteria, we are spearheading the development of the next generation of lifesaving treatments.

When the Cure Stops Working

The Antibiotic Era

For most of human history, an open wound was a potential death sentence. Antibiotics revolutionized medicine, transforming deadly infections into treatable conditions.

When Treatments Fall Short

Today, decades of overuse have allowed bacteria to evolve, creating antimicrobial resistance (AMR). Today, common illnesses are becoming harder to treat, leading to longer recoveries, higher costs, and increased mortality.

What We Do

The Next Generation of Precision Medicine

SNIPR is pioneering CRISPR-powered medicines to fight resistant bacteria with precision. Our technology uses bacteriophages (viruses that prey only on bacteria), engineered probiotics for targeted delivery, and CRISPR itself — the bacteria’s own defense system — turned against them.

Our Technology

 

How It Works

Reading about CRISPR therapies can sometimes feel like rocket science. But it doesn’t have to. While there is cutting-edge science and engineering behind the processes, the basics of each step of the process, what is does and how it does it, is easy to understand. Let’s break it down in 5 easy steps:

Step 1 Illustration
Step 1 Number

Find DNA String that Is Unique to the Target

First we identify DNA that uniquely exist in the bacteria we want to target, like pieces making the bacteria resistant to antibiotics.

Step 2 Illustration
Step 1 Number

Create Precision Agent Targeting that DNA

Using cutting edge technology, we mass produce this unique string of DNA, and attach it to an enzyme that will make it a target seeking agent.

Step 3 Illustration
Step 1 Number

Deliver the Agent Using Friendly Microbiota

We deliver the agent using harmless bacteria or viruses that seek out the bacteria we want to target.

Step 4 Illustration
Step 1 Number

Find the Sequence, Tear It Down

The moment the agent detects its programmed DNA sequence, it slices cleanly through the strand, disrupting vital processes and ensuring the targeted cell can no longer survive.

Step 5 Illustration
Step 1 Number

Spot the Threat, Leave the Rest Untouched

Only the cells carrying the exact DNA signature are neutralized—everything else remains untouched.

Going Global

Uniting Minds to Outpace Bacterial Resistance

Tackling antimicrobial resistance isn’t a solo mission, it’s a global collaboration. Backed by leading partners like the SPRIN-D, Cystic Fibrosis Foundation, Gates Foundation, CARB-X, and the European Investment Bank, our breakthroughs are advancing from the lab into clinical reality. These partnerships amplify our impact, ensuring that scientific discoveries translate into lifesaving solutions.

Partnerships

Who We Are

The People Behind the Vision

At the heart of SNIPR is a team of more than 30 scientists, united by one goal: to outsmart resistant bacteria. Our expertise spans microbiology, genetics, and drug development — but it’s our shared passion for saving lives that drives us forward.

Meet the Team

Sharing is Caring

To solve the AMR crisis, we need all hands on deck, so we have opened up our technology for free use in research across the world. This means that both academic and commercial research can benefit from our progress, and only pay for licenses if they base their own commercial products off it.

More than $90M Raised for Next-Gen Therapies

SNIPR raised $50M in 2019 in one of the largest Series A’s in Europe from four large European funds to advance CRISPR-based microbiome drugs to human clinical trials. In 2025, more than $40M was raised in a Series B round.

Collaborations

From Discovery to Delivery

We currently have five CRISPR-based products in our pipeline, addressing a wide spectrum of diseases and conditions. These programs span every stage of development, from early discovery research through Phase 2 clinical trials.

Pipeline

A Solid Foundation of Patents

The SNIPR scientists have made several innovative and novel discoveries which are being protected in several separate patent families – +30 of which have already granted as US patents.

Patents

Work With Us

SNIPR is the leading CRISPR Microbiome company. As a growing company we are always looking for new talents to join our team in the capital of Denmark, Copenhagen. Our working environment is fun, fast-paced, collaborative and outcome focused. If you are curious, smart and passionate about inventing tomorrow’s medicine then drop us a line.

Careers